Mesoblast (NASDAQ:MESO) Sees Unusually-High Trading Volume on Analyst Upgrade

by · The Markets Daily

Shares of Mesoblast Limited (NASDAQ:MESO – Get Free Report) saw unusually-strong trading volume on Thursday after Piper Sandler raised their price target on the stock from $11.00 to $15.00. Piper Sandler currently has an overweight rating on the stock. Approximately 1,283,734 shares were traded during trading, an increase of 78% from the previous session’s volume of 722,881 shares.The stock last traded at $15.00 and had previously closed at $12.25.

Several other brokerages also recently commented on MESO. Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Tuesday, September 24th. Jefferies Financial Group raised Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, August 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. Finally, StockNews.com downgraded Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $13.50.

Read Our Latest Report on Mesoblast

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MESO. Jane Street Group LLC lifted its position in shares of Mesoblast by 46.4% in the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after buying an additional 26,959 shares in the last quarter. XY Capital Ltd bought a new position in shares of Mesoblast during the 3rd quarter valued at approximately $244,000. Signaturefd LLC boosted its position in shares of Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after acquiring an additional 3,099 shares during the last quarter. Creative Planning purchased a new position in shares of Mesoblast in the third quarter valued at $147,000. Finally, Perkins Coie Trust Co increased its position in Mesoblast by 15.0% in the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after purchasing an additional 1,500 shares during the last quarter. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Trading Down 12.7 %

The stock’s 50 day moving average is $10.48 and its 200-day moving average is $8.28. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

About Mesoblast

(Get Free Report)

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Featured Stories